SILVESTRIS, Nicola
 Distribuzione geografica
Continente #
EU - Europa 1.175
NA - Nord America 963
AS - Asia 36
AF - Africa 5
OC - Oceania 1
Totale 2.180
Nazione #
US - Stati Uniti d'America 961
IE - Irlanda 605
SE - Svezia 350
IT - Italia 172
IN - India 32
DE - Germania 15
FI - Finlandia 14
AT - Austria 6
SC - Seychelles 5
FR - Francia 4
PL - Polonia 3
CN - Cina 2
ES - Italia 2
NL - Olanda 2
AU - Australia 1
CA - Canada 1
HK - Hong Kong 1
HN - Honduras 1
HR - Croazia 1
RU - Federazione Russa 1
SG - Singapore 1
Totale 2.180
Città #
Dublin 605
Nyköping 349
Princeton 268
Medford 107
Chandler 86
Messina 86
Ashburn 35
Pune 29
Arezzo 16
Milan 13
Paternò 11
Helsinki 10
Rheinfelden 10
New York 6
Pittsburgh 6
Rome 6
Vienna 6
Giardini-Naxos 4
Catania 3
Chicago 3
Gdansk 3
Hyderabad 3
Los Angeles 3
Barcelona 2
Bari 2
Bordeaux 2
Cedar Knolls 2
Florence 2
Gravina di Catania 2
Lappeenranta 2
Linguaglossa 2
Ozzano dell'Emilia 2
Paris 2
Patti 2
Piazza Armerina 2
Santa Clara 2
Aachen 1
Amsterdam 1
Borås 1
Denver 1
Elk Grove Village 1
Hong Kong 1
La Ceiba 1
Lentini 1
Moscow 1
Mountain View 1
Naples 1
Safety Harbor 1
Scandicci 1
Sydney 1
Syracuse 1
Ucria 1
Zagreb 1
Totale 1.711
Nome #
Actors on the Scene: Immune Cells in the Myeloma Niche 35
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 32
A moonshot approach toward the management of cancer patients in the COVID-19 time: What have we learned and what could the Italian network of cancer centers (Alliance against Cancer, ACC) do after the pandemic wave? 32
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 29
Hydroxy-propil-β-cyclodextrin inclusion complexes of two biphenylnicotinamide derivatives: Formulation and anti-proliferative activity evaluation in pancreatic cancer cell models 23
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 23
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do 22
Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002 22
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 22
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms]. FT Apoptosi, o morte cellulare programmata: meccanismi regolatori e fisiopatologia 22
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 22
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 22
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial 20
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 20
Expression and characterization of a novel recombinant cytotoxin II from Naja naja oxiana venom: A potential treatment for breast cancer 20
Rapid serological and SARS-CoV-2 RT-PCR assays: comparison performed simultaneously in symptomatic COVID-19 patients 20
Advances in EGFR-directed therapy in head and neck cancer 20
Basics and frontiers on pancreatic cancer for radiation oncology: Target delineation, SBRT, SIB technique, MRgRT, particle therapy, immunotherapy and clinical guidelines 20
The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme 19
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 19
The latest findings of PD-1/PD-L1 inhibitor application in gynecologic cancers 19
Angiogenesis in adenosquamous cancer of pancreas 19
MiR-144: A new possible therapeutic target and diagnostic/prognostic tool in cancers 19
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals 18
AIDS-related Kaposi's sarcoma: principal pathogenic mechanisms 18
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study 18
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 18
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 18
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 18
Adjuvant colon cancer chemotherapy: where we are and where we'll go 18
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 17
Adjuvant therapy in colon cancer 17
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 17
Rare histotypes of epithelial biliary tract tumors: A literature review 17
A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine 16
Varied functions of immune checkpoints during cancer metastasis 16
Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection 16
Arginase 1 (Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy 16
Current approaches for combination therapy of cancer: The role of immunogenic cell death 16
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 15
Vaccination for seasonal influenza in patients with cancer: Recommendations of the Italian Society of Medical Oncology (AIOM) 15
On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents 15
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery 15
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery 15
Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study 15
NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer 15
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 15
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment 15
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 14
Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma? 14
Antineoplastic drug-induced bradyarrhythmias 14
Laparoscopic vs. open mesorectal excision for rectal cancer: Are these approaches still comparable? A systematic review and meta-analysis 13
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 13
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 13
The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer 13
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples 13
[Paraneoplastic syndromes of the central nervous system] 13
Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine 13
Clinical meanings of rapid serological assay in patients tested for SARS-Co2 RT-PCR 13
[Indices of disease activity in systemic lupus erythematosus. Review of the literature] 13
COVID-19 pandemic and the crisis of health systems: The experience of the apulia cancer network and of the comprehensive cancer center Istituto tumori “Giovanni Paolo II” of Bari 13
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 13
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 13
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 12
A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers 12
Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM) 12
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 12
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 12
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 12
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 12
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer 12
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 12
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 11
Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review 11
Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis 11
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 11
Author's reply: To PMID 22443211. 11
Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM) 11
Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study 11
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 11
A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study 10
A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology 10
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 10
mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer 10
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 10
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue 10
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 10
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma 10
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 10
A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report 10
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 9
Lapatinib in breast cancer: clinical experiences and future perspectives 9
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 9
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 9
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 9
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer 9
Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective 9
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 9
Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study 9
Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy 8
Totale 1.513
Categoria #
all - tutte 10.810
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.810


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022388 0 0 0 0 0 0 0 0 8 0 0 380
2022/20231.548 307 183 131 7 28 93 32 45 663 9 13 37
2023/2024330 53 58 33 27 33 55 44 10 9 8 0 0
Totale 2.266